Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2015

01-12-2015 | Case Report

Eosinophilia and parotitis occurring early in clozapine treatment

Authors: Bochra Nourhène Saguem, Saoussen Bouhlel, Chaker Ben Salem, Bechir Ben Hadj Ali

Published in: International Journal of Clinical Pharmacy | Issue 6/2015

Login to get access

Abstract

Case presentation

Mr. S is a 32-year-old male with schizophrenia. Due to poor responses to various antipsychotic medications, he was started on clozapine with the dose titrated to 300 mg/day during a 4-week period. The weekly checks of the complete blood cell count showed gradual increases in the eosinophil count from normal values to 4320 per mm3. Mr. S did not have any symptoms except some increased salivation. Clozapine was suspended, and eosinophils gradually began to decline to the normal range. Clozapine was subsequently re-started and there were no changes in eosinophil counts. Mr. S exhibited improvement of symptoms but complained of acute auricular pain and increased salivation, 8 weeks after clozapine rechallenge. He also developed a swelling of his both parotid glands. The diagnosis of clozapine-induced parotitis was suggested. Symptomatic medication was prescribed with a favorable outcome.

Conclusion

We report a case of a patient who developed eosinophilia shortly after clozapine use, and then developed parotitis. There is debate in the literature over how to manage these complications of clozapine treatment. Generally they do not warrant clozapine discontinuation.
Literature
2.
3.
4.
go back to reference Kontoangelos K, Loizos S, Kanakakis J, Smyrnis N, Economou M, Bergiannaki JD, et al. Myocarditis after administration of clozapine. Eur Rev Med Pharmacol Sci. 2014;18(16):2383–6.PubMed Kontoangelos K, Loizos S, Kanakakis J, Smyrnis N, Economou M, Bergiannaki JD, et al. Myocarditis after administration of clozapine. Eur Rev Med Pharmacol Sci. 2014;18(16):2383–6.PubMed
5.
go back to reference Brooks KG, Thompson DF. A review and assessment of drug-induced parotitis. Ann Pharmacother. 2012;46(12):1688–99.CrossRefPubMed Brooks KG, Thompson DF. A review and assessment of drug-induced parotitis. Ann Pharmacother. 2012;46(12):1688–99.CrossRefPubMed
6.
7.
go back to reference Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced toxic hepatitis with skin rash. J Psychopharmacol. 2005;19(1):107.CrossRefPubMed Fong SY, Au Yeung KL, Tosh JM, Wing YK. Clozapine-induced toxic hepatitis with skin rash. J Psychopharmacol. 2005;19(1):107.CrossRefPubMed
8.
go back to reference Karmacharya R, Mino M, Pirl WF. Clozapine-induced eosinophilic colitis. Am J Psychiatry. 2005;162(7):1386–7.CrossRefPubMed Karmacharya R, Mino M, Pirl WF. Clozapine-induced eosinophilic colitis. Am J Psychiatry. 2005;162(7):1386–7.CrossRefPubMed
10.
go back to reference Roberts CE, Mortenson LY, Merrill DB, Rafizadeh N, Smith TE, Lieberman JA. Successful rechallenge with clozapine after eosinophilia. Am J Psychiatry. 2011;168(11):1147–51.CrossRefPubMed Roberts CE, Mortenson LY, Merrill DB, Rafizadeh N, Smith TE, Lieberman JA. Successful rechallenge with clozapine after eosinophilia. Am J Psychiatry. 2011;168(11):1147–51.CrossRefPubMed
11.
go back to reference Schuepbach D, Merlo MC, Kaeser L, Brenner HD. Successful challenge with clozapine in a history of eosinophilia. Int Clin Psychopharmacol. 1998;13(1):33–7.CrossRefPubMed Schuepbach D, Merlo MC, Kaeser L, Brenner HD. Successful challenge with clozapine in a history of eosinophilia. Int Clin Psychopharmacol. 1998;13(1):33–7.CrossRefPubMed
12.
go back to reference Floreani J, Bastiampillai T. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry. 2008;42(8):747–8.PubMed Floreani J, Bastiampillai T. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Aust N Z J Psychiatry. 2008;42(8):747–8.PubMed
13.
go back to reference Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res. 2011;45(10):1358–65.CrossRefPubMed Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K, Sack U. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res. 2011;45(10):1358–65.CrossRefPubMed
14.
go back to reference Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry. 1998;59(4):195–7.CrossRefPubMed Lucht MJ, Rietschel M. Clozapine-induced eosinophilia: subsequent neutropenia and corresponding allergic mechanisms. J Clin Psychiatry. 1998;59(4):195–7.CrossRefPubMed
15.
go back to reference Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1–3):204–13.CrossRefPubMed Roge R, Moller BK, Andersen CR, Correll CU, Nielsen J. Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far? Schizophr Res. 2012;140(1–3):204–13.CrossRefPubMed
16.
17.
go back to reference Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D. Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry. 1993;34(8):536–43.CrossRefPubMed Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D. Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry. 1993;34(8):536–43.CrossRefPubMed
18.
go back to reference Martin SD. Drug-induced parotid swelling. Br J Hosp Med. 1993;50(7):426.PubMed Martin SD. Drug-induced parotid swelling. Br J Hosp Med. 1993;50(7):426.PubMed
19.
go back to reference Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis: an immunological cause? Am J Psychiatry. 1996;153(6):840.PubMed Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T. Clozapine-induced parotitis: an immunological cause? Am J Psychiatry. 1996;153(6):840.PubMed
20.
go back to reference Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. Am J Psychiatry. 1995;152(2):297–8.CrossRefPubMed Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. Am J Psychiatry. 1995;152(2):297–8.CrossRefPubMed
21.
go back to reference Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry. 1995;56(11):511–3.PubMed Vasile JS, Steingard S. Clozapine and the development of salivary gland swelling: a case study. J Clin Psychiatry. 1995;56(11):511–3.PubMed
22.
go back to reference Davé M. Iatrogenic salivary gland swelling. J Pharm Technol. 1995;11:18–20. Davé M. Iatrogenic salivary gland swelling. J Pharm Technol. 1995;11:18–20.
23.
go back to reference Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry. 1996;153(3):445.PubMed Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling. Am J Psychiatry. 1996;153(3):445.PubMed
24.
go back to reference Patkar AA, Alexander RC. Parotid gland swelling with clozapine. J Clin Psychiatry. 1996;57(10):488.CrossRefPubMed Patkar AA, Alexander RC. Parotid gland swelling with clozapine. J Clin Psychiatry. 1996;57(10):488.CrossRefPubMed
25.
go back to reference Southhall K, Fernando N. Report of a rare medical complication on clozapine. Aust NZ J Psychiat. 1999;33:122–3.CrossRef Southhall K, Fernando N. Report of a rare medical complication on clozapine. Aust NZ J Psychiat. 1999;33:122–3.CrossRef
26.
go back to reference McKay D. Perhaps not so rare? Aust NZ J Psychiat. 2000;34(2):340–1. McKay D. Perhaps not so rare? Aust NZ J Psychiat. 2000;34(2):340–1.
27.
go back to reference Gouzien C, Valiamé A, Misdrahi D. Clozapine-induced parotitis: a case study. L’encéphale. 2014;40:81–5.CrossRefPubMed Gouzien C, Valiamé A, Misdrahi D. Clozapine-induced parotitis: a case study. L’encéphale. 2014;40:81–5.CrossRefPubMed
28.
go back to reference Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185(3):265–73.CrossRefPubMed Praharaj SK, Arora M, Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. Psychopharmacology. 2006;185(3):265–73.CrossRefPubMed
29.
go back to reference Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol. 2001;21(6):608–11.CrossRefPubMed Bai YM, Lin CC, Chen JY, Liu WC. Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Psychopharmacol. 2001;21(6):608–11.CrossRefPubMed
Metadata
Title
Eosinophilia and parotitis occurring early in clozapine treatment
Authors
Bochra Nourhène Saguem
Saoussen Bouhlel
Chaker Ben Salem
Bechir Ben Hadj Ali
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0163-7

Other articles of this Issue 6/2015

International Journal of Clinical Pharmacy 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.